Sorafenib for the treatment of hepatocellular carcinoma: a single-centre real-world study
Article Category: Research Article
Published Online: May 28, 2020
Page range: 233 - 236
Received: Nov 18, 2019
Accepted: Dec 01, 2019
DOI: https://doi.org/10.2478/raon-2020-0027
© 2020 Jurij Hanzel, Tajda Kosir Bozic, Borut Stabuc, Rado Jansa, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Background
Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma. Its efficacy in randomised controlled trials was demonstrated in patients with well-preserved liver function and good functional status. In the real-world setting, treatment is often offered to patients outside these criteria. We therefore performed a single-centre real-world cohort study on the efficacy of sorafenib in patients with hepatocellular carcinoma.
Patients and methods
We identified all patients with hepatocellular carcinoma initiating treatment with sorafenib between January 2015 and January 2018. The primary endpoint was overall survival (OS) since starting sorafenib. Clinical and demographic variables associated with survival were studied.
Results
The median OS was 13.4 months (95% CI 8.2–18.6). Multivariable Cox’s regression identified worse ECOG performance status (HR 2.21; 95% CI 1.56–3.16;
Conclusions
Careful selection of patients for treatment with sorafenib is of paramount importance to optimize outcomes.